Radiopharm Theranostics RADX

Radiopharm Theranostics Limited is a research and development company focused on developing and commercializing radiopharmaceutical products for diagnostic and therapeutic applications in precision oncology. The company develops targeted radiopharmaceutical technologies using peptides small molecules and antibodies attached to medical radioisotopes. It aims to obtain regulatory approval for its product candidates in major markets including the United States the European Union the United Kingdom China Japan Australia and Canada.

Radiopharm Theranostics Limited generates revenue through licensing agreements sublicensing fees royalty payments and potential future sales of its radiopharmaceutical products. The company has entered into exclusive license agreements with various institutions granting it rights to develop and commercialize specific technologies. It also earns income from strategic partnerships such as its collaboration with Lantheus Holdings which includes milestone payments and cost sharing for clinical development. Currently the company does not have any products approved for commercial sale so revenue is primarily derived from upfront payments and milestone achievements under its licensing and partnership arrangements.

The company operates through the following segments:

• Nano-mAbs: This segment involves the development of radiopharmaceuticals using genetically engineered camelid derived single domain antibodies nanobodies that target HER-2 PD-L1 and PTK7 receptors. The technology is designed for both diagnostic and therapeutic applications in cancers such as breast gastric and non-small cell lung cancer. RAD201 and RAD202 target HER-2 overexpression while RAD203 and RAD204 target PD-L1 in non-small cell lung cancer.
• Pivalate: This segment focuses on the development of 18 F-FPIA radiotracer for the detection and monitoring of brain metastases and glioblastoma. The technology targets fatty acid synthetase which is overexpressed in tumor cells but not in normal brain cells. RAD101 is in Phase IIb development for brain metastases imaging while RAD102 is being developed for therapeutic use in brain tumors.
• Avβ6-Integrin Trivehexin: This segment develops radiopharmaceuticals targeting the Avβ6 integrin which is overexpressed in tumors such as pancreatic carcinoma head-and-neck cancer and certain lung cancers. RAD301 is a diagnostic agent using Gallium 68 for PET imaging while RAD302 is a therapeutic version using Lutetium 177 for radionuclide therapy. The technology enables early detection and treatment of invasive tumors with high specificity.
• PSA-mAb: This segment involves a humanized monoclonal antibody targeting prostate specific antigen PSA in prostate cancer cells. The technology aims to provide a theranostic approach for prostate cancer by combining diagnostic imaging with therapeutic radionuclides such as Tb161. RAD401 and RAD402 are in pre-clinical and planned clinical stages respectively for prostate cancer applications.
• PTPµ PTPmu: This segment develops a peptide molecule biomarker for the detection imaging and treatment of tumors. The technology targets PTPµ which is expressed on tumor cells but not in healthy tissue. RAD601 and RAD602 are in pre-clinical stage with initial focus on glioblastoma. The agent functions as a PET imaging agent with low radiation and as a theranostic with high energy radiation.
• Radiopharm Ventures LLC: This segment is a joint venture with The University of Texas M. D. Anderson Cancer Center focused on developing therapeutic radiopharmaceutical products. The venture is developing a humanized immunoglobulin G antibody targeting B7-H3 also known as CD276 which is highly expressed in several solid tumors including prostate lung hepatocellular carcinoma pancreatic colorectal head and neck and breast tumors. The candidate is intended to eliminate resistant cancers in lab models and has received IND approval for a Phase I trial in the United States.

Radiopharm Theranostics Limited operates in the radiopharmaceutical and theranostics industry which is a specialized segment of the broader nuclear medicine and precision oncology sectors. The company competes with established players such as Novartis which markets Lutathera and Pluvicto Telix Pharmaceuticals which offers Illuccix and Pixclara and other firms like Point Bio and RayzeBio that have been acquired by larger pharmaceutical companies. Its competitive advantages lie in its diversified platform of six licensed technologies spanning nanobodies small molecules antibodies and peptides its joint venture with MD Anderson and its global intellectual property strategy seeking patent protection in key markets. The company’s focus on targets expressed exclusively on tumor cells and not healthy tissue aims to reduce off‑target effects and improve therapeutic index.

The company serves hospitals clinics research institutions and patients involved in oncology diagnosis and treatment. Its product candidates are intended for use in medical imaging departments and nuclear medicine facilities where PET SPECT and other radiopharmaceutical procedures are conducted. Specific customer names are not disclosed in the filing but the company collaborates with institutions such as Shanghai General Hospital Imperial College London Case Western Reserve University and The University of Texas M. D. Anderson Cancer Center for clinical development and trial execution.